linjc16/ctgov huggingface dataset:
Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate the effectiveness of robotic-assisted locomotor therapy on improvements of functional gait parameters in ambulatory children with cerebral palsy.

Detailed Description
-----------------
Within a randomized controlled design the effects of robotic-assisted locomotor training (15 sessions within 5 weeks) will be examined in a sample of 34 children with cerebral palsy. Children will be randomly assigned to an intervention or waiting list group. Assessments will be performed at baseline, in week 6 as well as in week 12. The intervention is provided to the waiting list group after the assessment in week 6.

Official Title
-----------------
Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy: A Randomized Controlled Clinical Trial Including 3D Gait Analysis

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Other: Lokomat training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bilateral spastic cerebral palsy Gross Motor Function Classification Scale (GMFCS) II-IV Exclusion Criteria: Prior orthopedic surgery on the lower extremity or the trunk (<6 months) Prior neurosurgical interventions (<6 months) Significant mental retardation Severe contractures Prior Lokomat training (<6 months)

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lokomat training<br>Lokomat training | Other: Lokomat training<br>* 15 sessions of Lokomat training within 5 weeks (3 trainings/week)<br>|
| Other: Waiting list<br>Lokomat training after waiting phase of 5 weeks | Other: Lokomat training<br>* 15 sessions of Lokomat training within 5 weeks (3 trainings/week)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GMFM-66, section E |  | week 0, week 6, week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GMFM-66, section D |  | week 0, week 6, week 12 | 
| Gait speed |  | week 0, week 6, week 12 | 
| 6-minute walk test |  | week 0, week 6, week 12 | 
| 3D gait analysis |  | week 0, week 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Child, Robotic-assisted treadmill training, Rehabilitation
Reasons for Emergency Department Utilization and Readmission in Postoperative 90 Days

Study Overview
=================
Brief Summary
-----------------
The objective of this study was conducted to examine the reasons for patients' utilization of the emergency department and the rates of readmission in the first 90 days after surgery.

Detailed Description
-----------------
Background: Postoperative readmission rates of patients have been important indicators in the evaluation of quality service delivery and cost-effectiveness. This study was conducted to examine the reasons for patients' utilization of the emergency department and the rates of readmission in the first 90 days after surgery. Material and methods: The research is based on actual patient data in the hospital information management system. In the study, the data of patients who had undergone surgery between January 1, 2018, and December 31, 2018, and presented to the emergency department in the first 90 days after surgery were retrospectively analyzed. Patient data about the date of surgery, type of surgery, department performing the surgery, patient age, gender, type of anesthesia, the length of postoperative hospital stay, date of discharge, date, and reason for presenting to the emergency department, and discharge status (admission, referral, discharge, or death, etc.) recorded on the hospital information management system were evaluated in accordance with the 18 HIPAA standards.

Official Title
-----------------
Reasons for Emergency Department Utilization and Readmission in Postoperative 90 Days: A Retrospective Analysis Based on the Hospital Information Management System

Conditions
-----------------
Surgery, Nursing Caries

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergone surgery between January 1, 2018, and December 31, 2018, Presented to the emergency department Exclusion Criteria: • Patients who do not meet the inclusion criteria
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|no intervention was made|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify the causes of preventable post-operative emergency utilization | the reasons for patients' utilization of the emergency department after surgery | January 1, 2018, and December 31, 2018, | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contribute to the strategic planning for quality health service delivery by determining the complaints and repeated admission rates by unit. | the reasons for applying complaints on the basis of clinics | January 1, 2018, and December 31, 2018, | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgery,, emergency department,, readmission
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.

Detailed Description
-----------------
This is a Natural History study in renal or renal-pancreas transplant recipients. In an effort to capture patients early in the course of an evolving BK virus infection and avoid patients who have already developed evidence of BKV-induced nephropathy (BKVN), this protocol will emphasize the initiation of screening in the early post-transplant period. Patients who have undergone renal or renal/pancreas transplantation within 4 weeks, but not more than 90 day previously, will be asked to participate and then consented to be enrolled in a Natural History-Surveillance period for up to approximately 24 months. Participants enrolled in this study will provide valuable natural history data regarding BKV viremia, and potentially other viral pathogen, in the post-renal transplant period. Participants will provide blood samples to undergo measurement for plasma BKV DNA by PCR approximately every 6 weeks, to be resulted in real time at the UAB Diagnostic Virology Laboratory at UAB.

Official Title
-----------------
Natural History of Infection Caused by BK Virus (and Other Opportunistic Viral Pathogens) in Renal Transplant Recipients

Conditions
-----------------
BK Virus (BKV) Viremia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Renal or renal-pancreas transplant patients who are within 4 weeks and not more than 90 days post-transplant with or without qualifying BKV viremia Age greater than or equal to 18 years; Provides written informed consent. Exclusion Criteria: Evidence of proven or suspected BKVN by clinical or pathologic diagnostic criteria Loss of renal graft function Initiation of chronic dialysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects | We will measure the number of subjects screened who develops BK viremia within 4 weeks and up to 24 months after renal transplant | within 4 weeks and up to 24 months after renal transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BK virus viremia, renal transplant, other viral pathogens
Comparison of Two Minimally Invasive Surgical Techniques for Hip Replacement

Study Overview
=================
Brief Summary
-----------------
Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty

Official Title
-----------------
Comparison of the Clinical Effectiveness and Cost-effectiveness of the MIS Anterolateral Approach (MIS Watson Jones, G3) Versus Anterolateral Mini or Posterolateral Mini Approaches in Primary Total Hip Arthroplasty

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Procedure: hip surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No contralateral hip symptoms, no major comorbidity Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-months WOMAC score |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost-effectiveness at 2-years |  | Two years |
DAW1033B2 in Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033B2 administered before sleep on OSA phenotype traits and OSA severity during sleep.

Official Title
-----------------
Effect of DAW1033B2 on Obstructive Sleep Apnea

Conditions
-----------------
Obstructive Sleep Apnea (OSA)

Intervention / Treatment
-----------------
* Drug: Placebo oral capsule
* Drug: DAW1033B2 oral capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criterion: OSA: AHI > 15 Exclusion Criteria: Any medical condition other than well controlled hypertension, diabetes, hyperlipidemia Any medication known to influence breathing, sleep/arousal or muscle physiology. Claustrophobia. Inability to sleep supine. Allergy to lidocaine, Oxymetazoline HCl, DAW1033D. Individuals with underlying cardiac disease, such as arrhythmias. Individuals taking psychiatric medications, or any of the studied medications for medical care. History of seizures For women: Pregnancy. History of panic disorder / hyperventilation syndrome / Attention deficit-hyperactivity disorder (ADHD) / autism

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Placebo before sleep | Drug: Placebo oral capsule<br>* Placebo capsule 30 minutes before sleep<br>|
| Experimental: DAW1033B2 oral capsule<br>DAW1033B2 before sleep | Drug: DAW1033B2 oral capsule<br>* DAW1033B2 capsule 30 minutes before sleep<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apnea Hypopnea Index (AHI, Events/Hour of Sleep) | Based on previous studies the investigators anticipate that DAW1032B2 will reduce AHI more effectively in subjects with moderate sleep apnea, mildly obese (BMI<32), Vpassive > 50% of Veupnea (ventilation during eupneic ventilatory drive) | 1 night |
Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.

Official Title
-----------------
A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, pre-menopausal female volunteers Exclusion Criteria: Acute or chronic disease which could influence the study results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of Primary Aldosteronism in Young Adults With Acute Stroke

Study Overview
=================
Brief Summary
-----------------
The guideline requires clinical works to screen for primary aldosteronism(PA) in young adults with family history of stroke at early onset. But the prevalence of PA in young adults with stroke onset before 45 years old had never been investigated. The study aimed to discover the prevalence as well as the clinical characteristics between patients with PA and those without PA during stroke attack. In order to fulfill this objective, investigators intended to conduct a cross-sectional study by taking screening and confirmatory tests among young adults who once admitted due to early onset of acute stroke.

Official Title
-----------------
Prevalence of Primary Aldosteronism in Young Adults With Acute Stroke

Conditions
-----------------
Primary Aldosteronism

Intervention / Treatment
-----------------
* Other: screening and confirmatory tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - patients who were once admitted in the First affiliated hospital of Chongqing Medical university(CQMU), with stroke onset less than two weeks Exclusion Criteria: death, serious sequela with motor, comprehensive or linguistic dysfunction, patients unwilling to join in, etiology of trauma, infective or tumor disease, patients with impaired cardiac, renal or liver function during admission-

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with PA<br>patients who finally been diagnosed with primary aldosteronism | Other: screening and confirmatory tests<br>* screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test<br>|
| patients without PA<br>patients who finally been diagnosed without primary aldosteronism | Other: screening and confirmatory tests<br>* screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of PA | to find out the proportion of PA patients in young adults with early onset of acute stroke | through study completion, an average of 2 years |
Thalidomide and Dacarbazine for Metastatic Melanoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two drugs will also be assessed. Dacarbazine is the standard medical treatment for metastatic melanoma. It has been shown to produce tumor shrinkage in approximately 20% of patients with advanced melanoma. This shrinkage is usually incomplete and lasts a short time. Thalidomide is a drug that inhibits tumor blood vessel growth. It can be given orally. It is hoped that this combination can be given to patients with metastatic melanoma without causing too much toxicity while increasing the response rate.

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Drug: thalidomide
* Drug: dacarbazine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with metastatic melanoma. Lesions must be measurable. Patient must have the following minimum labs: ANC> 1500/mm3, Hemoglobin > 8 mg/dl; platelets > 100,000 mm3; and liver function tests < 5x normal; and creatinine < 1.5 mg/dl. ECOG performance status > 2. No prior therapy with DTIC or thalidomide No other history of malignancy other than curatively resected basal cell carcinoma of the skin or carcinoma in situ of the cervix. Patients must not be pregnant or lactating. Sexually active men and women of childbearing age must use adequate contraception. All patients must understand the potential for severe birth defects with thalidomide and must be able to follow instructions to avoid conception while taking thalidomide

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: thalidomide|nan|
|Drug: dacarbazine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical study is to verify the long term effectiveness and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd. as a treatment option for patients with cognitive, behavioral, and functional disability of Tourette Syndrome.

Official Title
-----------------
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome

Conditions
-----------------
Tourette Syndrome

Intervention / Treatment
-----------------
* Device: deep brain stimulation (DBS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is aged 18 or older Patient Group with Tourette's syndrome, Diagnosis of Tourette Syndrome by DSM-IV Exclusion Criteria: Major Depressive Episode within the previous 6 months Schizophrenia or other psychotic disorder.Participate in other clinical trial; Has a life expectancy of < 1 year. The investigator and/or enrollment review committee, would preclude participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Deep Brain Stimulation<br>Deep Brain Stimulation is on | Device: deep brain stimulation (DBS)<br> <br> * Other names: Implanted device;|
| Sham Comparator: Sham Stimulation<br>placebo | Device: deep brain stimulation (DBS)<br> <br> * Other names: Implanted device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Rush Video Rating Scale (mRVRS) |  | 12 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tourette Syndrome Symptom List (TSSL) |  | 12 month | 
| SF-36 |  | 12 month |